TROP2-Targeted ADCs with Topoisomerase I Inhibitors Advance in Oncology
Antibody-drug conjugates targeting TROP2 with topoisomerase I inhibitor payloads are currently marketed in breast and lung cancer, with over 100 such ADCs now in clinical trials for various malignancies including gastrointestinal tumors.
Antibody-drug conjugates targeting TROP2 with topoisomerase I inhibitor chemotherapy payloads are currently marketed in breast and lung cancer, with their success fueling broader clinical development. Over 100 such ADCs have entered clinical trials to date.
Enhertu, Trodelvy, and Datroway are challenging standards of care for difficult-to-treat cancers. Overexpression of trophoblast cell surface antigen 2 (TROP2) has been identified in various malignancies, making it a target of high interest in current oncology with multiple TROP2-targeting agents in the investigative pipeline for a vast array of malignancies.
TROP2 ADCs currently in use carry unique toxicities and come with specifics in supportive care therapy. Combination strategies are also being explored.
Gastrointestinal malignancies represent a heterogeneous group of cancers—with some of the most common malignancies and some with a high incidence of cancer-related deaths—in dire need of newer therapies. Early phase 1/2 data show a spark of activity in reports on colorectal cancer and gastroesophageal cancer.
Studies are underway for targeting TROP2 in colorectal cancer, pancreatic cancer, biliary tract cancers, and gastroesophageal cancers. TROP2 investigation is highly prevalent in current oncology, and discovering more targeted therapy in GI malignancies is of utmost importance.